These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 32634132

  • 1. LIN28B promotes the development of neuroendocrine prostate cancer.
    Lovnicki J, Gan Y, Feng T, Li Y, Xie N, Ho CH, Lee AR, Chen X, Nappi L, Han B, Fazli L, Huang J, Gleave ME, Dong X.
    J Clin Invest; 2020 Oct 01; 130(10):5338-5348. PubMed ID: 32634132
    [Abstract] [Full Text] [Related]

  • 2. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR, Gan Y, Tang Y, Dong X.
    EBioMedicine; 2018 Sep 01; 35():167-177. PubMed ID: 30100395
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Lin28B/Let-7 Regulates Expression of Oct4 and Sox2 and Reprograms Oral Squamous Cell Carcinoma Cells to a Stem-like State.
    Chien CS, Wang ML, Chu PY, Chang YL, Liu WH, Yu CC, Lan YT, Huang PI, Lee YY, Chen YW, Lo WL, Chiou SH.
    Cancer Res; 2015 Jun 15; 75(12):2553-65. PubMed ID: 25858147
    [Abstract] [Full Text] [Related]

  • 5. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D.
    Nat Commun; 2020 Jan 17; 11(1):338. PubMed ID: 31953400
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
    Lee AR, Li Y, Xie N, Gleave ME, Cox ME, Collins CC, Dong X.
    Oncotarget; 2017 Apr 25; 8(17):27966-27975. PubMed ID: 28427194
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC.
    Clin Cancer Res; 2019 Nov 15; 25(22):6839-6851. PubMed ID: 31439587
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.
    Nat Commun; 2019 Jan 17; 10(1):278. PubMed ID: 30655535
    [Abstract] [Full Text] [Related]

  • 15. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
    Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, Alumkal JJ.
    Neoplasia; 2020 Jun 17; 22(6):253-262. PubMed ID: 32403054
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.
    Alam M, Ahmad R, Rajabi H, Kufe D.
    Mol Cancer Res; 2015 Mar 17; 13(3):449-60. PubMed ID: 25368430
    [Abstract] [Full Text] [Related]

  • 18. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
    Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T.
    Sci Rep; 2021 Jun 25; 11(1):13305. PubMed ID: 34172788
    [Abstract] [Full Text] [Related]

  • 19. Neoplastic Transformation of Human Mesenchymal Stromal Cells Mediated via LIN28B.
    Vishnubalaji R, Elango R, Al-Toub M, Manikandan M, Al-Rikabi A, Harkness L, Ditzel N, Atteya M, Hamam R, Alfayez M, Aldahmash A, Kassem M, Alajez NM.
    Sci Rep; 2019 May 30; 9(1):8101. PubMed ID: 31147574
    [Abstract] [Full Text] [Related]

  • 20. Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer.
    Sulsenti R, Scialpi GB, Frossi B, Botti L, Ferri R, Tripodi I, Piva A, Sangaletti S, Pernici D, Cancila V, Romeo F, Chiodoni C, Lecis D, Bianchi F, Fischetti I, Enriquez C, Crivelli F, Bregni M, Renne G, Pece S, Tripodo C, Pucillo CE, Colombo MP, Jachetti E.
    Cancer Immunol Res; 2024 Sep 03; 12(9):1147-1169. PubMed ID: 38869181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.